Data indicates potential of drug candidate to
deliver an extremely potent therapeutic benefit at a very low
non-toxic dose
New data will be presented at the 4th Annual
International Cannabinoid-Derived Pharmaceuticals Summit in
Boston
MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the
Company”), a clinical stage pharmaceutical company committed to
extending healthy lifespan, today announced new data demonstrating
Supera-CBD’s superior potency over CBD by factor of 8,000 times.
Supera-CBD is MyMD’s pre-clinical patented synthetic cannabidiol
(CBD) derivative that is being developed as a pharmaceutical drug
to address anxiety, pain, and neurodegeneration. The study was
conducted by Eurofins Discovery, a Eurofins Scientific (EUFI.PA)
company.
Supera-CBD targets the cannabinoid receptor type 2 (CB2), a
protein mainly expressed in the immune system and which is
associated with the therapeutic effects of CBD, including its
anxiolytic, anticonvulsant, antipsychotic, neuroprotective and
anti-inflammatory properties. CB2 receptors do not create an
intoxicating negative psychotropic reaction (e.g. a high). In
contrast, CB1 is usually expressed in the brain and distributed
throughout the central nervous system to deliver an intoxicating
effect. A vast majority of CBD developers are pursuing compounds
targeted to CB2 that have minimal CB1 affinity. Watch how
Supera-CBD works.
“We believe that the new data we are revealing today is an
extraordinary achievement in the field of pharmaceutical
cannabinoids,” said Adam Kaplin, M.D., Ph.D., Chief Scientific
Officer of MyMD. “We already knew from earlier pre-clinical studies
conducted by a major medical school that Supera-CBD presents a
dramatically higher binding affinity for the CB2 receptor as
compared with plant-derived CBD – a factor of four times. But what
happens after binding is what is most important to the efficacy of
CBD. Once the CBD binds to CB2, it must activate the receptor in
order to effect its action as a therapeutic agent. The new data
demonstrates what we believe to be the strikingly effective ability
of Supera-CBD to bind to and activate CB2 to potentially deliver an
extremely potent therapeutic benefit at a very low non-toxic
dose.
“Our drug candidate, with low CB1 affinity and four-fold
increased CB2 binding, is 8,000 times more potent a CB2 agonist
(activator) than regular CBD,” Dr. Kaplin continued. “As we are
working to make Supera-CBD a major value creator for our
shareholders moving forward, we couldn’t be more excited about a
research discovery of this magnitude at this stage of
development.”
In comparison to Supera-CBD, the synthetic cannabinoid CP 55940,
another highly potent activator of CB2, is also a highly potent
activator of CB1, delivering an intoxicating effect to the user.
For this reason, the compound was abandoned by its developer and
never marketed. Supera-CBD is estimated by MyMD to be between 40 to
500 times the potency of the first discovered and
best-characterized endocannabinoids anandamide and 2-arachidonoyl
glycerol, which are produced naturally inside the body.
Plant-derived CBD has almost no activity at the CB2 receptor,
and therefore has nearly zero potency as a medicinal drug.
Chris Chapman, M.D., President, Director and Chief Medical
Officer of MyMD, stated, “Building on CBD’s enormous pre-existing
market acceptance and the FDA’s declared receptiveness to moving
forward in this space, we believe that Supera-CBD can become not
only a prescription drug alternative to unregulated CBD, but the
pinnacle of the cannabinoid landscape. At 8,000 times the potency
of regular CBD, we believe that Supera-CBD shows strong potential
as a therapeutic for high-threat diseases and conditions like
Alzheimer's, psychosis, neuropathic pain, addiction, and anxiety.
The markets for these indications are massive, and given
Supera-CBD’s high potency with minimal toxicity, production costs
for very small yet highly effective doses would be low. Given the
remarkable data we are announcing today, we are optimistic that the
future opportunity for our synthetic CBD drug candidate is
enormous. We look forward to providing continuing updates as we
advance this drug candidate in the clinic.”
Dr. Kaplin will deliver an oral presentation of the new
Supera-CBD data today at the 4th Annual International
Cannabinoid-Derived Pharmaceuticals Summit in Boston,
Massachusetts. His presentation, “Synthetic Superactive Supera-CBD
Supersedes CBD,” will be delivered before a prestigious audience of
expert scientists, thought leaders, and delegates representing
premier institutions and corporations worldwide.
Supera-CBD is currently on a path toward human clinical trials
as a therapy for epilepsy, followed by chronic pain.
About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals,
Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical company
committed to extending healthy lifespan, is focused on developing
two novel therapeutic platforms that treat the causes of disease
and decline rather than only addressing the symptoms. MYMD-1 is a
drug platform based on a clinical stage small molecule that
regulates the immunometabolic system to control TNF-α, a driver of
chronic inflammation, and other pro-inflammatory cell signaling
cytokines. MYMD-1 is being developed to treat aging and longevity,
autoimmune diseases, and COVID-19-associated depression and
cytokine elevation. The Company’s second drug platform, Supera-CBD,
is being developed to treat chronic pain, addiction and epilepsy.
Based on a novel synthetic derivative of cannabidiol (CBD),
Supera-CBD is being developed to address the rapidly growing CBD
market, which includes both FDA approved drugs and CBD products not
currently regulated as drugs. For more information, visit
www.mymd.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release may contain forward-looking statements. These
forward-looking statements involve known and unknown risks,
uncertainties and other factors which may cause actual results,
performance or achievements to be materially different from any
expected future results, performance, or achievements.
Forward-looking statements speak only as of the date they are made
and none of MyMD nor its affiliates assume any duty to update
forward-looking statements. Words such as "anticipate," "believe,"
"could," "estimate," "expect," "may," "plan," "will," "would'' and
other similar expressions are intended to identify these
forward-looking statements. Important factors that could cause
actual results to differ materially from those indicated by such
forward-looking statements include, without limitation: the timing
of, and MyMD’s ability to, obtain and maintain regulatory approvals
for clinical trials of MyMD’s pharmaceutical candidates; the timing
and results of MyMD’s planned clinical trials for its
pharmaceutical candidates; the amount of funds MyMD requires for
its pharmaceutical candidates; increased levels of competition;
changes in political, economic or regulatory conditions generally
and in the markets in which MyMD operates; MyMD’s ability to retain
and attract senior management and other key employees; MyMD’s
ability to quickly and effectively respond to new technological
developments; MyMD’s ability to protect its trade secrets or other
proprietary rights, operate without infringing upon the proprietary
rights of others and prevent others from infringing on MyMD’s
proprietary rights; and the impact of the ongoing COVID-19 pandemic
on MyMD’s results of operations, business plan and the global
economy. A discussion of these and other factors with respect to
MyMD is set forth in the Quarterly Report on Form 10-Q for the
quarterly period ended June 30, 2021, filed by MyMD on August 16,
2021. Forward-looking statements speak only as of the date they are
made and MyMD disclaims any intention or obligation to revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210922005168/en/
Investor Contact: Robert Schatz (646) 421-9523
rschatz@mymd.com www.mymd.com
Media Contact: media@mymd.com
MyMD Pharmaceuticals (NASDAQ:MYMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
MyMD Pharmaceuticals (NASDAQ:MYMD)
Historical Stock Chart
From Apr 2023 to Apr 2024